Xiaobin Wu Sells 280 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 280 shares of BeOne Medicines stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The shares were sold at an average price of $276.26, for a total value of $356,927.92.
• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The shares were sold at an average price of $266.76, for a total value of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total value of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total value of $399,745.08.

BeOne Medicines Stock Down 1.5%

ONC stock opened at $366.73 on Friday. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The firm has a 50 day simple moving average of $325.53 and a 200-day simple moving average of $311.31. The company has a market capitalization of $40.26 billion, a P/E ratio of 64.57 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on ONC. TD Cowen increased their target price on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target for the company. Wolfe Research restated an “outperform” rating and set a $370.00 price objective on shares of BeOne Medicines in a research note on Monday, August 10th. Royal Bank Of Canada reduced their price objective on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Barclays lifted their price objective on shares of BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $402.14.

Institutional Trading of BeOne Medicines

Several hedge funds have recently made changes to their positions in ONC. EFG International AG bought a new position in BeOne Medicines during the 4th quarter worth $25,000. Leonteq Securities AG bought a new stake in BeOne Medicines during the 4th quarter valued at $35,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines during the second quarter valued at about $35,000. CWM LLC lifted its stake in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines in the fourth quarter worth approximately $61,000. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.